NOVOME BIOTECHNOLOGIES, INC.
Engineered bacterial strains with prebiotic-controlled colonization and on-demand clearance mechanisms for therapeutic delivery in the human gut
- Sector
- Biotech
- Headquarters
- DALY CITY, CA
- Founded
- 2015
- Latest Form D
- $536K, Jan 2017
- Total capital
- $1.5M
- Federal grants
- $975K
- 2 awards · 2016–2018
- Rank in peer group#256 of 326
- Private capital raised
- $536K
- 1 Form D · last Jan 2017
- 118 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 21 pending · first 2022
- Rank in peer group#58 of 326
Capital timeline
Latest events
- Federal grantNSF · Phase II · SBIR Phase II: Establishing a Synthetic Niche to Reliably Colonize the Human Gut with Engineered Bacterial Therapeutics$750K
- Private capital raisedForm D · SEC · 1st filing$536K
- Federal grantNSF · Phase I · SBIR Phase I: Establishing a Synthetic Niche to Reliably Colonize the Human Gut with Engineered Bacterial Therapeutics$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
1month
from NOVOME BIOTECHNOLOGIES, INC.’s first federal award to its first private round.
- First federal award · Dec 2016
- NSF · $225K
- First Form D · Jan 2017
- $536K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#58 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Weston WhitakerResearcherExecutive Officer, Director, PromoterLinked by $975K in grants as PI
- Elizabeth StanleyDirectorNamed in SEC Form D filings
- Samuel SmitsDirectorNamed in SEC Form D filings
- William DeLoacheDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 23- PendingMethods And Compositions For Treating Disorders Associated With Bile AcidsUSPTOApplication 18228870
- PendingBiologically Contained Bacteria And Uses ThereofUSPTOApplication 17618130
- GrantedCompositions And Methods For Modulating Growth Of A Genetically Modified Gut Bacterial CellUSPTOUS 11,566,238
Show all 23 patent records
- Methods And Compositions For Treating Disorders Associated With Bile AcidsOct 3, 2024 · Application 18228870Pending
- Biologically Contained Bacteria And Uses ThereofJul 25, 2024 · Application 17618130Pending
- Compositions And Methods For Modulating Growth Of A Genetically Modified Gut Bacterial CellJan 31, 2023 · US 11,566,238Granted
- Oral Administration Of Genetically Engineered BacteriaNov 17, 2022 · Application 17763014Pending
- Plasmids For Gene EditingSep 15, 2022 · Application 17432753Pending
- Compositions and Methods for Modulating Growth of a Genetically Modified Gut Bacterial CellJun 9, 2022 · Application 17675721Pending
- Compositions and Methods for Modulating Growth of a Genetically Modified Gut Bacterial CellFeb 22, 2022 · US 11,254,918Granted
- Engineered Gut Microbes And Uses ThereofApr 1, 2021 · Application 16967382Pending
- Compositions And Methods For Modulating Growth Of A Genetically Modified Gut Bacterial CellFeb 21, 2019 · Application 16047862Pending
- Methods And Compositions For Treating Disorders Associated With Bile AcidsApplication PCTUS2022014991Pending
- Oral Administration Of Genetically Engineered BacteriaApplication PCTUS2020052582Pending
- Recombinant Fusion Polypeptides For Secreting Soluble, Heterologous CargoApplication 63409592Pending
- Biologically Contained Bacteria And Uses ThereofApplication PCTUS2020037571Pending
- Methods And Compositions For Treating HyperoxaluriaApplication PCTUS2019065446Pending
- Oral Administration Of Genetically Engineered BacteriaApplication 62904924Pending
- Biologically Contained Bacteria And Uses ThereofApplication 62861181Pending
- Compositions And Methods For Modulating Growth Of A Genetically Modified Gut Bacterial CellApplication 18145526Pending
- Plasmids For Gene EditingApplication 62809869Pending
- Methods And Compositions For Treating HyperoxaluriaApplication 62777322Pending
- Engineered Gut Microbes And Uses ThereofApplication 62626586Pending
- Compositions And Methods For Modulating Growth Of A Genetically Modified Gut Bacterial CellApplication PCTUS2017066408Pending
- Methods And Compositions For Treating Bile Acid DisordersApplication 63144715Pending
- Compositions And Methods For Modulating Growth Of A Genetically Modified Gut Bacterial CellApplication 62435048Pending
Related companies, and why
- Serotiny, Inc.Similar federal contract value in Biotech · null in contracts
- Berkeley Fermentation Science Inc.Similar federal contract value in Biotech · null in contracts
- BACTANA CORP.Similar federal contract value in Biotech · null in contracts
- Ichor Biologics LLCSimilar federal contract value in Biotech · null in contracts
- CryptoMedix, Inc.Similar federal contract value in Biotech · null in contracts
- Vcreate, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .